Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... BioProcess International (BPI), a business-to-business ... BioProcess International Awards. The awards celebrate the outstanding ... technology applications that will allow the industry to ... patient base. , Winners and finalists were honored ... entertaining and exciting awards dinner and ceremony yesterday ...
(Date:10/25/2014)... Iowa (PRWEB) October 24, 2014 ... Perdue plans to more than double the acreage ... in geographies supplying its soybean crush facility in ... from this program will target several markets including ... alternatives with good performance. , For the 2015 ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... Quarter 2009 Financial ResultsVANCOUVER, April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... a conference call discussing its financial results for the first ... at 11:00 AM ET (8:00 AM Pacific)., ... is as, follows:, North ...
... Aspheric NTIOL Implanted through the Smallest Micro-Incision using ... Assist Ophthalmic PracticesMONROVIA, Calif., April 16 STAAR ... leading developer, manufacturer and marketer of minimally invasive ... Afinity Collamer Aspheric Single Piece New Technology Intraocular ...
... April 15 Cytopia Limited (ASX: CYT) announced that ... agent (VDA) CYT997 at the forthcoming 100th Annual Meeting ... Colorado, USA. Dr David Segal, Principal Scientist at Cytopia, ... Research: Experimental and Molecular Therapeutics 2 poster session ...
Cached Biology Technology:STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 2STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 3STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 4STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 5Cytopia Presentation on VDA CYT997 at AACR Conference 2
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... Endogens Screening Sets contain the ... develop five colorimetric sandwich ELISA plates ... in 100 l/well of cell culture ... and Detection Antibodies, Recombinant Standard (5 ...
... The organic acid analysis standard ... six organic salts; molecular weights ... This standard is provided for ... column and the organic acid ...
Biology Products: